Table 2 Overview of vaccine targeting... | American Society of Hematology

Table 2

Overview of vaccine targeting approaches

Vaccine	Species	Targeting moiety	Adjuvant	Adjuvant- antigen linked?	Reference
Protein conjugate	Mouse	αDec-205 Ab	αCD40 Ab, MALP-2,	No	16,78
			Pam₃Cys, polyI:C, polyICLC
			LPS, R848, CpG
			CpG	Yes	93
		αMR Ab	CpG	No	17
		αLangerin Ab	PolyI:C, PolyICLC, αCD40 Ab	No	60
		αDC-SIGN Ab	None	No	99
		αDectin-1 Ab	PolyI:C	No	18
		αClec9A Ab	PolyI:C, PolyICLC, αCD40 Ab,	No	60,34,100
			Curdlan
		αSiglec-H Ab	CpG	No	29,30
		Lewis-X or -B*	None	No	101
		Tn antigen†	CpG, alum, αCD40 Ab	No	19
		αBST-2 Ab	PolyI:C	No	28
	Human	αDec-205 Ab	CD40 Ligand	No	102
		αMR Ab	R848, MALP-2, Loxoribine,	No	103
			Pam₃CSK₄, Flagellin, LPS,
			PolyI:C, CD40 Ligand
		αDC-SIGN Ab	PolyI:C, R848	No	20
		αDCIR Ab	PolyI:C, LPS, CL075, CD40	No	21,104
			Ligand, CpG-C, Loxoribine
		αClec9A Ab	PolyI:C, R848	No	44,105
		Oxidized mannan‡	None	No
Polymer particle	Mouse	αDec-205 Ab	Particle composition	Yes	¹⁰⁶
	Mouse	αDec-205 Ab	PolyI:C, R848	Yes	⁹¹
	Human	αDC-SIGN Ab	PolyI:C, R848	Yes	⁹¹
Liposome	Mouse	αDec-205 Ab	IFNγ or LPS	Yes	⁹⁶
		Mannose‡	Pam₃CAG, Pam₂CAG,	Yes	⁶⁶
			Pam₂CGD
		Lewis-X or -B*	—	—	¹⁰⁷
		Lewis A or tri-	—	—	¹⁰⁸
		GlcNAc‡
		Mannopentaose‡	—	—	¹⁰⁹
	Human	αDec-205 Ab	—	—	110
	Human	αDC-SIGN Ab	—	—	111
Virus	Mouse	CD40 Ligand	CD40 Ligand	Yes	95
		Mutated Sindbis	—	—	94
		Virus glycoprotein*
	Human	αDC-SIGN Ab	—	—	112
		αCD40 scFv	αCD40 scFv	No	113
		CD40 Ligand	CD40 Ligand	Yes	114

Vaccine	Species	Targeting moiety	Adjuvant	Adjuvant- antigen linked?	Reference
Protein conjugate	Mouse	αDec-205 Ab	αCD40 Ab, MALP-2,	No	16,78
			Pam₃Cys, polyI:C, polyICLC
			LPS, R848, CpG
			CpG	Yes	93
		αMR Ab	CpG	No	17
		αLangerin Ab	PolyI:C, PolyICLC, αCD40 Ab	No	60
		αDC-SIGN Ab	None	No	99
		αDectin-1 Ab	PolyI:C	No	18
		αClec9A Ab	PolyI:C, PolyICLC, αCD40 Ab,	No	60,34,100
			Curdlan
		αSiglec-H Ab	CpG	No	29,30
		Lewis-X or -B*	None	No	101
		Tn antigen†	CpG, alum, αCD40 Ab	No	19
		αBST-2 Ab	PolyI:C	No	28
	Human	αDec-205 Ab	CD40 Ligand	No	102
		αMR Ab	R848, MALP-2, Loxoribine,	No	103
			Pam₃CSK₄, Flagellin, LPS,
			PolyI:C, CD40 Ligand
		αDC-SIGN Ab	PolyI:C, R848	No	20
		αDCIR Ab	PolyI:C, LPS, CL075, CD40	No	21,104
			Ligand, CpG-C, Loxoribine
		αClec9A Ab	PolyI:C, R848	No	44,105
		Oxidized mannan‡	None	No
Polymer particle	Mouse	αDec-205 Ab	Particle composition	Yes	¹⁰⁶
	Mouse	αDec-205 Ab	PolyI:C, R848	Yes	⁹¹
	Human	αDC-SIGN Ab	PolyI:C, R848	Yes	⁹¹
Liposome	Mouse	αDec-205 Ab	IFNγ or LPS	Yes	⁹⁶
		Mannose‡	Pam₃CAG, Pam₂CAG,	Yes	⁶⁶
			Pam₂CGD
		Lewis-X or -B*	—	—	¹⁰⁷
		Lewis A or tri-	—	—	¹⁰⁸
		GlcNAc‡
		Mannopentaose‡	—	—	¹⁰⁹
	Human	αDec-205 Ab	—	—	110
	Human	αDC-SIGN Ab	—	—	111
Virus	Mouse	CD40 Ligand	CD40 Ligand	Yes	95
		Mutated Sindbis	—	—	94
		Virus glycoprotein*
	Human	αDC-SIGN Ab	—	—	112
		αCD40 scFv	αCD40 scFv	No	113
		CD40 Ligand	CD40 Ligand	Yes	114

Representative targeting studies are grouped by vaccine design. In addition, information on the presence and form of adjuvant in the vaccine formulations of these studies is depicted.

Binds to DC-SIGN.

†

Binds to MGL.

‡

Binds to MR.

View Large

This Feature Is Available To Subscribers Only